Amarin Corp Plc (AMRN)

[ziploc_1]

Capt..Thanks for posting this interesting article, which expands on the Evaporate study...

A very short summary of the abstract...

QUOTE..."The EVAPORATE trial demonstrated that IPE significantly reduced plaque burden. No study to date has assessed the impact of IPE on coronary physiology. Fractional flow reserve (FFR) derived from coronary computed tomography angiography (CTA) data sets (FFRCT) applies computational fluid dynamics to calculate FFR values in epicardial coronary arteries. Our objective was to assess the impact of IPE on coronary physiology assessed by FFRCT using imaging data from EVAPORATE....
Conclusion...
Icosapent ethyl demonstrated significant benefits in coronary physiology compared with placebo. This early and sustained improvement in FFRCT at 9- and 18-month follow-up provides mechanistic insight into the clinical benefit observed in the REDUCE-IT trial. Furthermore, this is the first assessment of FFRCT to determine drug effect on coronary physiology assessed by FFRCT using imaging data from EVAPORATE."...

We are getting ever closer to the mechanism by which EPA(Vascepa) reduces CVD.

P.S....to Dr. Nessen...MINERAL OIL HAD NOTHING TO DO WITH THESE FINDINGS!!